Diligence memo · auto-generated · as of July 2, 2026
Cormatrix Cardiovascular Inc
Cormatrix Cardiovascular Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Cormatrix Cardiovascular Inc operates in Biotechnology, based in Roswell.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cormatrix Cardiovascular Inc has raised $34M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $25M on 2011-07-01.
Most recent recorded round closed around 2018-07-01.
Valuation (modeled)modeled
Provath models Cormatrix Cardiovascular Inc at approximately $318M (range $16M–$1.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.40× the median modeled value of Series B Biotechnology companies in 2016–2018 (101 peers) — value vs value, same stage and era. Issuer reports $5M–$25M revenue while modeled below niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 17 months.
Last raise 8.0 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 8.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 76% of Biotechnology peers (4293 compared).
Modeled value ranks above 77% of those peers.
Closest niche peers: Liquid BioScience, Inc., Amphivena Therapeutics, Inc., Tracon Pharmaceuticals, Inc., Tetra Discovery Partners, Inc., ECM Therapeutics, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.